

Table of Contents

Preface *xix*

Volume I

| | | |
|----------|--|----------|
| 1 | Inflammation through the Ages: A Historical Perspective | 1 |
| | <i>Jean-Marc Cavaillon</i> | |
| 1.1 | Introduction | 1 |
| 1.2 | The First Treatments | 1 |
| 1.3 | The Definitions | 3 |
| 1.4 | Fever | 3 |
| 1.5 | Phagocytosis | 4 |
| 1.6 | Diapedesis | 6 |
| 1.7 | Chemotactism | 7 |
| 1.8 | Infection and Inflammation | 8 |
| 1.9 | Usefulness of Inflammation for Adaptive Immune Response | 9 |
| 1.10 | Mediators of Inflammation | 10 |
| | References | 12 |

Part One Inducers and Sensors of Inflammation 17

| | | |
|----------|---|-----------|
| 2 | Pathogen-associated Molecular Patterns | 19 |
| | <i>Jean-Marc Cavaillon</i> | |
| 2.1 | Definition | 19 |
| 2.2 | Endotoxin | 20 |
| 2.2.1 | Brief Historical Background | 20 |
| 2.2.2 | Biochemical Characteristics | 21 |
| 2.2.3 | Detection | 23 |
| 2.2.4 | Natural Ligands | 24 |
| 2.2.5 | Cell Activation | 25 |
| 2.2.6 | Tolerance | 26 |
| 2.3 | Other Bacterial PAMPs | 26 |
| 2.3.1 | Lipoproteins | 26 |
| 2.3.2 | Lipoteichoic Acid | 27 |
| 2.3.3 | Flagellin | 28 |

| | | |
|----------|---|-----------|
| 2.3.4 | Peptidoglycan | 28 |
| 2.3.5 | Fimbriae | 30 |
| 2.3.6 | Glycogolipids | 30 |
| 2.3.7 | Heat Shock Proteins | 30 |
| 2.3.8 | Bacterial DNA | 31 |
| 2.3.9 | Bacterial RNA | 32 |
| 2.4 | Viral PAMPs | 33 |
| 2.5 | Parasitic PAMPs | 35 |
| 2.6 | Fungal PAMPs | 36 |
| 2.7 | Synergy | 37 |
| | References | 38 |
| 3 | Damage-associated Molecular Patterns | 57 |
| | <i>Jean-Marc Cavaillon</i> | |
| 3.1 | Definition | 57 |
| 3.2 | Necrosis versus Apoptosis | 58 |
| 3.3 | Receptors of Danger Signals | 58 |
| 3.4 | Main DAMPs | 60 |
| 3.4.1 | High-mobility Group Box 1 | 60 |
| 3.4.2 | Heat Shock Protein | 61 |
| 3.4.3 | RNA and DNA | 62 |
| 3.4.4 | Mitochondria | 62 |
| 3.4.5 | Histones | 62 |
| 3.4.6 | Uric Acid Crystals | 63 |
| 3.4.7 | ATP | 63 |
| 3.4.8 | S100A8/S100A9 | 64 |
| 3.4.9 | Interleukin-1 α and Interleukin-33 | 64 |
| 3.4.10 | Heme | 65 |
| 3.4.11 | Hyaluronan | 65 |
| 3.4.12 | Biglycan | 66 |
| 3.4.13 | Heparan Sulfate | 66 |
| 3.4.14 | Eosinophil-derived Neurotoxin | 66 |
| 3.4.15 | Peroxiredoxins | 67 |
| | References | 67 |
| 4 | Bacterial Toxins | 81 |
| | <i>Marina de Bernard and Cesare Montecucco</i> | |
| 4.1 | Introduction | 81 |
| 4.2 | Toxins Modulating the Activity of Inflammatory Caspases and Inflammasomes | 82 |
| 4.3 | Toxins Modulating the Intracellular cAMP Levels | 84 |
| 4.4 | Toxins Modulating MAPK Signaling | 85 |
| 4.4.1 | Synergy between ET and LT | 86 |
| 4.5 | Toxins Affecting Host Cell Motility | 87 |
| 4.6 | Toxins Blocking Protein Synthesis or Protein Folding | 88 |
| 4.7 | Conclusions | 89 |
| | References | 90 |

| | | |
|----------|---|---------------------------|
| 5 | Venoms | 99 |
| | <i>Catarina Teixeira, Vanessa Moreira, and José María Gutiérrez</i> | |
| 5.1 | Introduction | 99 |
| 5.2 | Inflammation Induced by Snake Venoms | 100 |
| 5.3 | Inflammation Induced by Scorpion Venoms | 105 |
| 5.4 | Inflammation Induced by Spider Venoms | 107 |
| 5.5 | Inflammation Induced by Venoms of Bees, Vespids, and Ants | 110 |
| 5.6 | Conclusions | 112 |
| | References | 113 |
| | | |
| 6 | Hypoxia as an Inducer of Inflammation | 129 |
| | <i>Ariel Brandwein and Clifford S. Deutschman</i> | |
| 6.1 | Introduction | 129 |
| 6.2 | Oxygen Sensing | 130 |
| 6.3 | Mitochondrial Oxygen Sensing | 131 |
| 6.4 | The Role of Transcription Factors | 132 |
| | 6.4.1 Hypoxia-Inducible Factor | 133 |
| | 6.4.2 Nuclear Factor κ B | 135 |
| 6.5 | The Warburg Effect | 135 |
| 6.6 | Acute versus Chronic Hypoxia | 136 |
| 6.7 | Inflammasome Activation | 137 |
| 6.8 | Summary and Conclusions | 139 |
| | References | 139 |
| | | |
| 7 | Vaccine Adjuvants | 143 |
| | <i>Dennis M. Klinman and Hidekazu Shirota</i> | |
| 7.1 | Introduction | 143 |
| 7.2 | Adjuvants Approved for Human Use | 144 |
| 7.3 | Aluminum Compounds: The Gold Standard | 144 |
| 7.4 | AS04 | 145 |
| 7.5 | Calcium Phosphate | 145 |
| 7.6 | Emulsions | 146 |
| | 7.6.1 IFA and CFA | 146 |
| | 7.6.2 MF59 | 146 |
| | 7.6.3 AS03 | 147 |
| 7.7 | Nano/microparticles Including Liposomes and Viroosomes | 148 |
| 7.8 | Immune Stimulating Complexes | 148 |
| 7.9 | Cytokines | 149 |
| | 7.9.1 IL-12 | 149 |
| | 7.9.2 IL-2 | 149 |
| | 7.9.3 IL-15 | 150 |
| | 7.9.4 GM-CSF | 150 |
| 7.10 | Adjuvants that Target Toll-like Receptors | 150 |
| | 7.10.1 Introduction | 150 |
| | 7.10.2 TLR2 | 151 |
| | | 7.10.2.1 Overview 151 |
| | | 7.10.2.2 TLR2 ligands 151 |

| | | |
|----------|--|------------|
| | 7.10.2.3 Clinical Activity | 151 |
| | 7.10.2.4 Safety | 152 |
| 7.10.3 | TLR3 | 152 |
| | 7.10.3.1 Overview | 152 |
| | 7.10.3.2 TLR3 Ligands and Their Immunogenicity | 152 |
| | 7.10.3.3 Safety | 153 |
| 7.10.4 | TLR4 | 153 |
| | 7.10.4.1 Overview | 153 |
| | 7.10.4.2 TLR4 Ligands | 153 |
| | 7.10.4.3 Clinical Activity | 153 |
| | 7.10.4.4 Safety | 154 |
| 7.10.5 | TLR5 | 154 |
| | 7.10.5.1 Overview | 154 |
| 7.10.6 | TLR7/8 | 154 |
| | 7.10.6.1 Overview | 154 |
| | 7.10.6.2 TLR7/8 Ligands and Their Preclinical Activity | 155 |
| | 7.10.6.3 Clinical Activity | 155 |
| | 7.10.6.4 Safety | 155 |
| 7.10.7 | TLR9 | 156 |
| | 7.10.7.1 Overview | 156 |
| | 7.10.7.2 TLR9 Ligands | 156 |
| | 7.10.7.3 Clinical Activity | 156 |
| | 7.10.7.4 Safety | 157 |
| 7.11 | Adjuvant Combinations | 157 |
| 7.12 | Future Directions | 157 |
| | References | 158 |
| 8 | Pattern Recognition Receptors | 175 |
| | <i>Lauren Whitehead and Gordon D. Brown</i> | |
| 8.1 | Introduction | 175 |
| 8.2 | Toll-like Receptors | 176 |
| | 8.2.1 Cell Surface-bound TLRs | 177 |
| | 8.2.2 Endosomal TLRs | 178 |
| | 8.2.3 TLR Signaling | 179 |
| | 8.2.4 MyD88-dependent Signaling Pathway | 179 |
| | 8.2.5 TRIF Signaling Pathway | 179 |
| 8.3 | C-type Lectin Receptors | 181 |
| | 8.3.1 DC-SIGN | 181 |
| | 8.3.2 Mannose Receptor | 182 |
| | 8.3.3 Surfactant Protein D | 182 |
| 8.4 | Natural Killer Gene Complex-associated CLR | 183 |
| | 8.4.1 Activation Receptors | 183 |
| | 8.4.2 Inhibitory Receptors | 185 |
| | 8.4.3 CLR Signaling | 186 |
| 8.5 | RIG-1-like Receptors | 187 |
| | 8.5.1 RLR Signaling | 188 |

| | | |
|-------|---|-----|
| 8.6 | NOD-like Receptors | 189 |
| 8.6.1 | NOD1 and NOD2 | 191 |
| 8.6.2 | NOD1 and NOD2 Signaling | 192 |
| 8.6.3 | NLRC4 | 192 |
| 8.6.4 | NLRPs | 192 |
| 8.7 | DNA-sensing Molecules | 193 |
| 8.7.1 | Signaling Components of DNA-sensing Molecules | 194 |
| 8.7.2 | Cross-talk between PRRs | 195 |
| 8.8 | Conclusions | 195 |
| | Acknowledgments | 196 |
| | References | 196 |

Part Two Inflammatory Cells 217

| | | |
|-----------|--|-----|
| 9 | Monocytes and Macrophages | 219 |
| | <i>Irina N. Shalova, Shilpi Saha, and Subhra K. Biswas</i> | |
| 9.1 | Introduction | 219 |
| 9.2 | Origin and Differentiation | 219 |
| 9.3 | Activation and Polarization | 221 |
| 9.4 | Functions | 222 |
| 9.4.1 | Cytokine Production and Inflammation | 223 |
| 9.4.2 | Phagocytosis | 224 |
| 9.4.3 | Antigen Presentation | 226 |
| 9.4.4 | Migration | 227 |
| 9.4.5 | Immunoregulation | 228 |
| 9.4.6 | Vascular Functions | 229 |
| 9.5 | Molecular Pathways and Mechanisms Regulating Response | 230 |
| 9.5.1 | Signaling Pathways | 230 |
| 9.5.2 | Epigenetic Regulation | 232 |
| 9.5.3 | Micro-RNAs | 234 |
| 9.6 | Conclusions | 235 |
| | Acknowledgment | 235 |
| | References | 236 |
| 10 | Neutrophils | 253 |
| | <i>Salvatore Cuzzocrea</i> | |
| 10.1 | Characteristics | 253 |
| 10.2 | Hematopoiesis | 254 |
| 10.3 | Adhesion and Migration | 255 |
| 10.3.1 | Traffic and Margination | 255 |
| 10.3.2 | Adhesion to the Endothelial Wall | 256 |
| 10.3.3 | Transendothelial Migration | 257 |
| 10.4 | Phagocytosis and Degranulation | 258 |
| 10.4.1 | Phagocytosis | 258 |
| 10.4.2 | Degranulation | 259 |

| | | |
|-----------|--|------------|
| 10.5 | Cytokine Synthesis | 260 |
| 10.5.1 | TNF- α | 260 |
| 10.5.2 | IL-1 and IL-1 Receptor Antagonist | 260 |
| 10.5.3 | IL-8 as a Model of Chemokines | 261 |
| 10.5.4 | Modulation of Cytokine Expression and Production by Neutrophils | 261 |
| 10.6 | Neutrophil Apoptosis | 261 |
| 10.7 | Neutrophils in Pathology | 262 |
| 10.7.1 | Bacterial Infection | 263 |
| 10.7.2 | Tissue Injury-induced Inflammation: Ischemia-reperfusion Injury | 263 |
| 10.7.3 | Crystal-induced Inflammation | 263 |
| 10.7.4 | Cytokine-induced Inflammation: Rheumatoid Arthritis | 263 |
| 10.7.5 | Autoimmunity Against Neutrophil Components: Antineutrophil Cytoplasmic Antibodies and Vasculitis | 264 |
| 10.7.6 | Genetic Disorders of Neutrophil Regulations: Hereditary Periodic Fever Syndromes | 264 |
| 10.7.7 | Cystic Fibrosis: Neutrophil-mediated Tissue Damage and Concomitant Persistence of Infection | 265 |
| 10.8 | Conclusions | 265 |
| | References | 266 |
| 11 | Mast Cells: Master Drivers of Immune Responses against Pathogens | 273 |
| | <i>W.X. Gladys Ang and Soman N. Abraham</i> | |
| 11.1 | Introduction | 273 |
| 11.2 | Biology of Mast Cells | 273 |
| 11.3 | Role of Mast Cells in Immune Surveillance | 275 |
| 11.3.1 | Strategic Peripheral Location | 275 |
| 11.3.2 | Direct Recognition of Pathogens | 275 |
| 11.3.3 | Indirect Recognition of Pathogens | 276 |
| 11.3.4 | Activation by Endogenous Danger Signals | 276 |
| 11.3.5 | Degranulation and Secretory Responses to Pathogens | 277 |
| 11.4 | Mast Cells in Innate Immunity | 278 |
| 11.4.1 | Direct Bactericidal Activity of Mast Cells | 278 |
| 11.4.2 | Resistance to Exo- and Endotoxins | 278 |
| 11.4.3 | Induction of Immune Cell Trafficking to Sites of Infection | 279 |
| 11.5 | Mast Cells in Adaptive Immunity | 279 |
| 11.5.1 | Mast Cells as Effectors of Adaptive Immunity | 279 |
| 11.5.2 | Recruitment of DCs and Effector T Cells to Sites of Infection | 280 |
| 11.5.3 | Recruitment of Dendritic Cells and T Cells to Draining Lymph Nodes | 280 |
| 11.5.4 | Antigen Presentation | 280 |
| 11.6 | Enhancement of Immunity by Boosting Mast Cell Activity | 281 |
| 11.6.1 | Mast Cell Activators as Novel Vaccine Adjuvants | 281 |
| 11.6.2 | Synthetic Mast Cell Granules | 281 |

| | | |
|-----------|--|------------|
| 11.7 | Potentially Detrimental Roles of Mast Cell Activation during Immune Responses | 282 |
| 11.7.1 | Overactivation of Mast Cells | 282 |
| 11.7.2 | Negative Modulation of Immunity by Mast Cells | 283 |
| 11.8 | Concluding Remarks | 283 |
| | Acknowledgments | 284 |
| | References | 284 |
| 12 | Dendritic Cells in Inflammatory Disease | 289 |
| | <i>Bart N. Lambrecht, Martin Guilliams, and Hamida Hammad</i> | |
| 12.1 | What Defines a Dendritic Cell? | 289 |
| 12.2 | Dendritic Cell Subsets | 290 |
| 12.3 | Dendritic Cells and T-cell Polarization | 291 |
| 12.4 | Dendritic Cells in Allergic Inflammation | 292 |
| 12.4.1 | Dendritic Cells are Necessary and Sufficient for Induction of Th2 Immunity | 292 |
| 12.4.2 | Different Subtypes of DCs Induce Th2 Immunity | 293 |
| 12.4.3 | Dendritic Cells are Also Required for Effector Th2 Immune Responses to Allergens | 294 |
| 12.4.4 | DCs Get Activated Directly after Exposure to Allergen | 295 |
| 12.4.5 | Lung DCs Activated Indirectly by Epithelial Cells | 296 |
| 12.5 | Inflammatory DCs' Role in Human Allergy | 298 |
| 12.6 | Dendritic Cells in Autoimmune Inflammatory Disease | 298 |
| 12.7 | Conclusions | 299 |
| | References | 300 |
| 13 | Roles for NK Cells and ILC1 in Inflammation and Infection | 315 |
| | <i>Christian A.J. Vosshenrich and James P. Di Santo</i> | |
| 13.1 | Introduction | 315 |
| 13.2 | Distinguishing Group 1 ILC and NK Cells | 316 |
| 13.3 | NK Cell and ILC1 Activating and Inhibitory Receptors | 317 |
| 13.3.1 | Natural Cytotoxicity Receptors | 317 |
| 13.3.2 | NKG2D | 318 |
| 13.3.3 | DNAX Accessory Molecule-1 (DNAM-1, CD226) | 318 |
| 13.3.4 | MHC Class I-specific Receptors and NK Cell "Education" | 318 |
| 13.3.5 | Are ILC1s "Educated" Similar to Conventional NK Cells? | 319 |
| 13.4 | Evidence for Distinct Subsets of NK Cells and ILC1 | 319 |
| 13.5 | Effector Functions of NK Cells and ILC1 | 320 |
| 13.6 | NK Cells and Group 1 ILCs in Inflammation and Infection | 322 |
| 13.6.1 | Mouse Cytomegalovirus | 322 |
| 13.6.2 | Influenza Virus | 323 |
| 13.6.3 | NK Cells and Other Viral Infections | 324 |
| 13.6.4 | Salmonella | 324 |
| 13.6.5 | Listeria monocytogenes | 325 |
| 13.6.6 | Mycobacteria and Other Bacteria | 325 |

| | | |
|-----------|---|------------|
| 13.7 | NK Cell and ILC1 Memory | 326 |
| 13.8 | Concluding Remarks: NK and ILC1 as Partners in a Type 1 Network | 327 |
| | References | 329 |
| 14 | Group 2 and 3 Innate Lymphoid Cells: New Actors in Immunity and Inflammation | 341 |
| | <i>Nicolas Serafini and James P. Di Santo</i> | |
| 14.1 | ILCs: A New Family of Innate Effector Cells | 341 |
| 14.2 | ILC2 and ILC3 Heterogeneity and Homeostasis | 342 |
| 14.3 | ILC2 in Acute and Chronic Inflammation | 345 |
| 14.4 | ILC3 in Acute and Chronic Inflammation | 348 |
| 14.5 | Therapeutically Harnessing ILC2 and ILC3 | 351 |
| 14.6 | Concluding Remarks | 352 |
| | References | 353 |
| 15 | Th9 Cells: From the Bench to the Bedside and Back Again | 365 |
| | <i>Benjamin J. Ulrich, Matthew M. Hufford, and Mark H. Kaplan</i> | |
| 15.1 | The History of T Helper Cells | 365 |
| 15.2 | Introduction to Th9 Cells | 367 |
| | 15.2.1 Development | 367 |
| | 15.2.2 Additional Th9-inducing Cytokines | 368 |
| | 15.2.3 Th9-inducing Cell Surface Ligands | 369 |
| | 15.2.4 The Function of Th9 Cells | 369 |
| 15.3 | Th9 Cells in Disease: The Helpful and Unhelpful | 371 |
| | 15.3.1 Tumor Immunity | 372 |
| | 15.3.2 Helminth Immunity | 372 |
| | 15.3.3 Inflammatory Bowel Disease | 373 |
| | 15.3.4 Allergic Inflammation | 374 |
| | 15.3.5 Dermatitis | 376 |
| | 15.3.6 Food Allergy | 377 |
| 15.4 | Targeting Th9 Cells Therapeutically | 377 |
| | 15.4.1 Th9 Differentiation | 377 |
| | 15.4.1.1 Cytokines and Costimulators Required for Differentiation | 377 |
| | 15.4.1.2 Transcription Factors for Differentiation | 379 |
| | 15.4.1.3 Factors Required for Promotion of Th9 Biology | 380 |
| | 15.4.2 Th9-associated Effector Molecules | 381 |
| 15.5 | Summary and Future Directions | 382 |
| | References | 382 |
| 16 | Th17 Cells | 395 |
| | <i>Mélissa Noack and Pierre Miossec</i> | |
| 16.1 | Introduction | 395 |
| 16.2 | Differentiation of Th17 Cells | 396 |
| | 16.2.1 Th17 Cell Differentiation in Mice | 396 |
| | 16.2.2 Th17 Cell Differentiation in Humans | 397 |

| | | |
|-----------|---|------------|
| 16.2.3 | Pathogenic Th17 Cells | 398 |
| 16.2.4 | Circulating versus Tissue Phenotypes | 398 |
| 16.3 | Cytokines and Chemokines Related to Th17 Cells | 399 |
| 16.3.1 | Major Cytokines and Chemokines Produced by Th17 Cells | 399 |
| 16.3.1.1 | IL-17A (IL-17)/IL-17F | 399 |
| 16.3.1.2 | IL-21 | 400 |
| 16.3.1.3 | IL-22 | 400 |
| 16.3.1.4 | CCL20 | 400 |
| 16.3.2 | Major Cytokines Acting on Th17 Cells | 401 |
| 16.3.2.1 | IL-23 | 401 |
| 16.3.2.2 | IL-27 | 401 |
| 16.4 | Th17 and Inflammatory Diseases | 401 |
| 16.4.1 | Psoriasis | 402 |
| 16.4.2 | Arthritic Diseases | 402 |
| 16.4.3 | Multiple Sclerosis | 403 |
| 16.4.4 | Inflammatory Bowel Diseases | 403 |
| 16.5 | Mechanisms in Chronic Inflammation | 403 |
| 16.5.1 | Differentiation, Recruitment, and Maintenance of Th17 Phenotype during Chronic Inflammation | 403 |
| 16.5.2 | Secretion of IL-17 and its Activity | 404 |
| 16.6 | Plasticity of Th17 Cells | 405 |
| 16.7 | Clinical Targeting of Th17 Cells | 407 |
| 16.8 | Conclusions | 408 |
| | Acknowledgment | 408 |
| | References | 408 |
| 17 | Platelets | 419 |
| | <i>Jack Levin</i> | |
| 17.1 | Introduction | 419 |
| 17.2 | Expression of Toll-like Receptors | 422 |
| 17.3 | Interactions between Platelets and Bacteria | 422 |
| 17.4 | Interactions between Platelets and White Blood Cells | 423 |
| 17.5 | Platelet Integrins | 424 |
| 17.6 | Role of Platelets in Immune Responses | 425 |
| 17.7 | Platelets and Inflammatory Disorders | 425 |
| 17.8 | Malaria | 426 |
| 17.9 | Systemic Lupus Erythematosus | 426 |
| 17.10 | Conclusions | 426 |
| | References | 427 |
| 18 | Epithelial Cells | 437 |
| | <i>Jill M. Hoffman and Charalabos Pothoulakis</i> | |
| 18.1 | Introduction | 437 |
| 18.2 | The Intestinal Epithelium: An Archetypal Epithelial Barrier | 438 |
| 18.3 | Choosing a Cell Fate: The Absorptive Lineage | 438 |
| 18.4 | Choosing a Cell Fate: The Secretory Lineage | 439 |

| | | |
|--------|--|-----|
| 18.4.1 | Goblet Cells | 439 |
| 18.4.2 | Paneth Cells | 441 |
| 18.4.3 | Enteroendocrine Cells | 441 |
| 18.5 | The Epithelium: The Sum is Greater than its Parts | 442 |
| 18.6 | Epithelial Homeostasis: Maintaining the Balance | 443 |
| 18.6.1 | Wnt Signaling | 443 |
| 18.6.2 | Notch Signaling | 444 |
| 18.6.3 | Inflammation-induced Alterations in Epithelial Cells | 445 |
| 18.7 | Concluding Remarks | 447 |
| | References | 447 |

| | | |
|-----------|---|-----|
| 19 | Inflammation: The Role of Endothelial Cells | 457 |
| | <i>J. Steven Alexander, D. Neil Granger, and Norman R. Harris</i> | |
| 19.1 | Introduction | 457 |
| 19.2 | Vasomotor Dysfunction | 458 |
| 19.2.1 | Mechanism of Vascular Smooth Muscle Contraction/ relaxation | 459 |
| 19.2.2 | Endothelial Cell-dependent Vasoactivity | 459 |
| 19.2.3 | Endothelium-dependent Vasoactivity in IBD | 460 |
| 19.2.3.1 | Leukocyte- and Platelet-endothelial Cell Adhesion | 461 |
| 19.2.3.2 | Enhanced Thrombosis | 463 |
| 19.2.3.3 | Angiogenesis/vasculogenesis | 465 |
| 19.2.3.4 | Junctional and Vascular Permeability | 468 |
| 19.3 | Conclusions | 470 |
| | References | 471 |

Volume II

Part Three Inflammatory Mediators 477

| | | |
|-----------|---|-----|
| 20 | IL-1 Superfamily and Inflammasome | 479 |
| | <i>Charles A. Dinarello</i> | |
| 21 | TNF Superfamily | 529 |
| | <i>Salvatore Cuzzocrea</i> | |
| 22 | Interleukin-17 A-E | 549 |
| | <i>Giovanni Monteleone, Irene Marafini, and Edoardo Troncone</i> | |
| 23 | IL-6 Superfamily | 573 |
| | <i>Toshio Tanaka, Masashi Narazaki, and Tadamistu Kishimoto</i> | |
| 24 | Type I and II Cytokine Superfamilies in Inflammatory Responses | 587 |
| | <i>William F. Carson IV and Steven L. Kunkel</i> | |

- 25 **Chemokines and Chemotaxis** 619
Osamu Yoshie and Kouji Matsushima
- 26 **Lipid Mediators in Inflammation** 651
Shuh Narumiya, Takehiko Yokomizo, and Junken Aoki
- 27 **Free Radicals in Inflammation** 695
Andrew Cumpstey and Martin Feelisch
- 28 **Proteases** 727
Celine Deraison, Chrystelle Bonnard, and Nathalie Vergnolle
- 29 **Psychiatric Disorders and Inflammation** 767
Robert Dantzer
- 30 **Complement System** 785
Peter A. Ward and Claudia Kemper
- 31 **Heat Shock Proteins** 813
Willem van Eden, Femke Broere, and Ruurd van der Zee

Volume III

Part Four Inflammation and Host Response 831

- 32 **Inflammation and Coagulation** 833
Marcel Levi
- 33 **Fever: Mediators and Mechanisms** 861
Joachim Roth
- 34 **Pain** 891
Christoph Stein
- 35 **Inflammation, Hormones, and Metabolism** 915
Muska Khpal and Mervyn Singer
- 36 **Microenvironmental Regulation of Innate Immune Cell Function** 947
Emily R. Watts, Eilise Ryan, Sarah R. Walmsley, and Moira K.B. Whyte
- 37 **Epigenetics of Inflammation** 971
Vidula Vachharajani and Charles E. McCall

Part Five Inflammation and Diseases 993

- 38 Allergy and Inflammation 995**
Milena Sokołowska, Anna Głobińska, and Cezmi A. Akdis
- 39 Sepsis 1031**
Manu Shankar-Hari and Mervyn Singer
- 40 Autoimmunity and Inflammation 1053**
Shrikant Ramesh Mulay, Onkar P. Kulkarni, Khader Rupanagudi, and Hans-Joachim Anders
- 41 Psoriasis and Other Skin Inflammatory Diseases 1091**
Jaehwan Kim and James G. Krueger
- 42 Rheumatoid Arthritis and Other Inflammatory Articular Diseases 1105**
Rogier M. Thurlings, Sander W. Tas, and Paul Peter Tak
- 43 Missing Heritability of Crohn's Disease and Implications for Therapeutic Targeting and Improved Care 1141**
Matthias Chamillard
- 44 Inflammation and Transplantation 1147**
William M. Baldwin, III and Robert L. Fairchild
- 45 Inflammatory Mechanisms in Chronic Obstructive Pulmonary Disease 1173**
Peter J. Barnes
- 46 Obesity: A Complex Disease with Immune Components 1199**
Yuejun Liu and Karine Clément
- 47 Inflammation and Type 2 Diabetes 1225**
Marleen M.J. van Greevenbroek, Casper G. Schalkwijk, and Coen D.A. Stehouwer
- 48 Inflammation-Mediated Neurodegeneration: Models, Mechanisms, and Therapeutic Interventions for Neurodegenerative Diseases 1255**
Hui-Ming Gao, Yun Gao, Dezhen Tu, Yue Liu, Hui Zhou, and Jau-Shyong Hong
- 49 Inflammation in Atherosclerosis 1279**
Mario A.R. Lauterbach, Larisa I. Labzin, and Eicke Latz

- 50 **Acute Kidney Injury** 1301
Johan Mårtensson and Rinaldo Bellomo
- 51 **Ischemia–Reperfusion Syndrome** 1313
Christophe Adrie, Sally A. Shin, and Mehran Monchi
- 52 **Single-Nucleotide Polymorphisms and Inflammation** 1329
Evangelos J. Giamarellos-Bourboulis

Volume IV

Part Six Resolution of Inflammation and Tissue Repair 1347

- 53 **Pentraxins in the Orchestration of Defense and Tissue Repair during the Acute Phase Response** 1349
Alberto Mantovani, Cecilia Garlanda, and Barbara Bottazzi
- 54 **Anti-Inflammatory Cytokines, Soluble Receptors, and Natural Antagonists** 1363
Willem Joost Wiersinga and Tom van der Poll
- 55 **Regulatory T Cells** 1377
Luciana Berod, Katharina Lahl, Matthias Lochner, Christian T. Mayer, and Tim Sparwasser
- 56 **Leukocyte Reprogramming** 1423
Jean-Marc Cavailon
- 57 **Roles of Specialized Proresolving Lipid Mediators in Inflammation Resolution and Tissue Repair** 1447
Matthew Spite and Charles N. Serhan
- 58 **Glucocorticoids** 1467
Heming Nicholas and Annane Djillali
- 59 **The Neuroimmune Communicatome in Inflammation** 1485
Peder S. Olofsson, Christine N. Metz, and Valentin A. Pavlov
- 60 **The Inflammatory Response in Tissue Repair** 1517
Nikolaos G. Frangogiannis

Part Seven Detection and Treatments 1539

- 61 **Biomarkers in Inflammation** 1541
Andreas Kortgen and Michael Bauer

- 62 ***In Vivo* Imaging of Inflammation** 1567
Anne Roivainen and Antti Saraste
- 63 **Novel Targets for Drug Development** 1583
Alan S. Cross and Steven M. Opal
- 64 **Inflammation and Microbiota and Gut Reconditioning** 1609
Stig Bengmark
- 65 **Natural Products as Source of Anti-Inflammatory Drugs** 1661
Shivaprasad H. Venkatesha, Bodhraj Acharya, and Kamal D. Moudgil